Prophylactic and Therapeutic Antibodies

Up until recently, most antibody therapeutics have been indicated for Inflammatory diseases and cancer. With the establishment of antibodies as therapeutics in these disease areas, there has been an expansion to a broader group of diseases such as infection, metabolic diseases, pain, Alzheimer, and bone diseases. With this expansion into new indications comes a new level of challenge. The meeting will address developing antibodies for prophylactic- or chronic-use indications that have traditionally been dominated by small molecule therapeutics, with case studies describing the development of antibodies for these market places; how molecule choices, dosing and delivery, and clinical design for efficacy and the minimization of safety risk all impact success. We will also address up and coming approaches such as antibody engineering for pharmacokinetic and pharmacodynamic improvements, the use of vaccines to induce humoral responses in vivo, and use of antibodies to deliver vaccines, as well as look back at what has been learned from chronic therapy of immune diseases. This meeting will be held in conjunction with the B cell meeting with an overlapping session on antibody diversity, as well as host workshops focusing on antibody specificity, crossing the blood braining barrier, and the use of smaller-bodies and polyclonal antibodies to address these new indications. It is anticipated that the attendees will come away with an appreciation of these challenges and that the meeting will stimulate research and novel solutions for addressing this group of indications.
+ show speakers and program
Keynote Address
Joseph Miletich, Amgen, USA
Antibody Therapeutic Indications: Expanding Beyond Cancer and Inflammatory Diseases

Jason G. Cyster, HHMI/University of California, San Francisco, USA
Lymphocyte Migration

Mark Brown, Pfizer, USA
Overview of Analgesic Efficacy and Safety of Tanezumab, a Monoclonal Antibody Targeting Nerve Growth Factor for Treatment of Chronic Pain

John A. Latham, Alder Biopharmaceuticals, USA
The Discovery and Development of an Anti-CGRP Antibody ALD403 for the Treatment of Migraine

Stephen P. Squinto, Alexion Pharmaceuticals, Inc., USA
Treatment of Hemolytic Diseases with Inhibitors of the Complement Cascade

Barry P. Sleckman, Washington University School of Medicine, USA
Pathways of Normal and Aberrant RAG Double Strand Break Repair in Developing B Cells

Cornelis Murre, University of California, San Diego, USA
Global Analysis of Long-Range Genomic Interactions that Orchestrate B Cell Fate

Hassan Jumaa, Max Planck Institute for Immunobiology, Germany
Pre B Cell Development

Neil Stahl, Regeneron Pharmaceuticals, USA
Reduction of LDL with the Inhibition of PCSK9 by REGN727

Peter Libby, Brigham and Women's Hospital, USA
Inflammation and Atherosclerosis: A Rationale for Antibody Treatment

Estelle Trifilieff, Novartis Institutes for Biomedical Research, Switzerland
Restore and Maintain Strong Body through Antibody Treatment in Skeletal Muscle Wasting Diseases

Christopher C. Goodnow, Australian National University, Australia
B Cell Self-Tolerance

Ann Marshak-Rothstein, University of Massachusetts Medical School, USA
(De-)Regulation of B Cell Activation

Roberta Pelanda, National Jewish Health, USA
Positive and Negative Selection of Primary B Cells

Herren Wu, MedImmune, USA
Engineering Biosuperiors

Javier Chaparro-Riggers, Rinat/Pfizer Inc., USA
Engineering pH-Sensitive Binding to a PCSK9 Antibody for Improved Pharmacokinetics and Efficacy

Tomoyuki Igawa, Chugai Pharmaceutical, Japan
Bispecific IgG Antibody Against FIXa and FX (ACE910) for the Treatment of Hemophilia A

Facundo D. Batista, Cancer Research UK, London Research Institute, UK
Dynamic Imaging of Lymphocyte Activation: From Single Molecule to Living Tissue

Susan K. Pierce, NIAID, National Institutes of Health, USA
B Cell Responses in Malaria

Tomohiro Kurosaki, WPI Immunology Frontier Research Center, Osaka University, Japan
B Cell Differentiation

Jeffrey V. Ravetch, Rockefeller University, USA
Regulating B Cell Activation

Bruce Roberts, Genzyme Corporation, USA
From Campath to Lemtrada: MOA and Clinical Path for the Treatment Multiple Sclerosis

Andreas Grauer, Amgen, USA
Targeting Osteoporosis: Increasing Bone Strength with Antibodies Against RANK-L and Sclerostin

Iain Chessell, MedImmune, UK
Antibody Therapeutics in Neuroscience

Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
B Cell Memory to Infection

Patrick C. Wilson, University of Chicago, USA
The Human B Cell Response to Viral Infection

Hedda Wardemann, Max-Planck Institute for Infection Biology, Germany
B Cell Selection

Jaap Goudsmit†, Crucell Holland B.V., Netherlands
Vaccines versus Antibody Therapy for the Treatment of Infectious Disease

Jeanine Wiener-Kronish, Massachusetts General Hospital, USA
Treatment of Pseudomonas aeruginosa Infection with Antibody Therapeutics

Deborah C. Molrine, University of Massachusetts of Medical School, USA
Antibody Mixtures: Treating Clostridium with an Antibody Combination

JoAnn Suzich, MedImmune, USA
A Novel Multi-Mechanistic Monoclonal Antibody for Treating P. aeruginosa Infections

Marc K. Jenkins, University of Minnesota Medical School, USA
Origins of CD4+ Memory T Cells

Michael G. McHeyzer-Williams, The Scripps Research Institute, USA
Regulating B Cell Immunity

Carola G. Vinuesa, Australian National University, Australia
Selection of Memory B Cells

Shane Crotty, La Jolla Institute for Allergy and Immunology, USA
T Cell Help to B Cells: Differentiation and Function of Follicular Helper CD4 T Cells (Tfh)

Peter M. Palese, Mount Sinai School of Medicine, USA
The Next Generation of Anti-Influenza Antibody Inducing Vaccines

Daniel Zagury, Neovacs SA, France
Active and Passive Anticytokine Immune Therapies: Current Status and Development

Ronald G. Crystal, Weill Medical College of Cornell University, USA
Viral Vectors as Platforms for Anti-Addiction Vaccines

Ira Mellman, Genentech, Inc., USA
Antibody Mediated Antigen Delivery for Vaccine Antigens to Dendritic Cells

David M. Tarlinton, Walter and Eliza Hall Institute of Medical Research, Australia
B Cell Responses

Mark J. Shlomchik, Yale University School of Medicine, USA
Germinal Center Selection and the Development of Memory B and Plasma Cells

Michel C. Nussenzweig, HHMI/Rockefeller University, USA
Germinal Center Biology

Max D. Cooper, Emory University, USA
Immune System Ontogeny and Phylogeny

David G. Schatz, Yale University School of Medicine, USA
Targeting of V(D)J Recombination and Somatic Hypermutation

Cristina Rada, MRC Laboratory of Molecular Biology, UK
Ig Gene Mutagenesis

Frederick W. Alt, Boston Children's Hospital, USA
Mechanisms of CSR and SHM

Marc Feldmann, University of Oxford, UK
Antibody Therapy of Rheumatoid Arthritis: Getting Closer to a Cure

Thomas A. Waldmann, National Institutes of Health, USA
T-Cell Cytokine Receptors: Targets for Monoclonal Antibody Mediated Treatment of Lymphoma and Autoimmune Diseases

Stephen T. Holgate, Southampton General Hospital, UK
Treating Asthma with Antibody Therapeutics

Klaus Rajewsky, Max Delbrück Center for Molecular Medicine, Germany
B Cell Immune Regulation

Louis M. Staudt, NCI, National Institutes of Health, USA
Therapies Targeting Pathological Signaling in B Cell Lymphomas

Riccardo Dalla-Favera, Columbia University, USA
Human Germinal Center B Cell Tumors

9 Feb - 14 Feb 2014
Keystone
United States of America
meeting website